{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:31:55Z","timestamp":1747182715666,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"27","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This phase II trial was designed to evaluate the efficacy and safety of S\u20101 combined with weekly irinotecan as a second\u2010 or third\u2010line treatment for patients with advanced or recurrent squamous cell lung cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with a body surface area\u2009&lt;1.25, 1.25\u20131.50, and\u2009&gt;1.50\u2009m<jats:sup>2<\/jats:sup> received oral S\u20101 on days 1\u201314 at 80, 100, and 120\u2009mg\/day, respectively, and irinotecan on days 1 and 8 at 70\u2009mg\/m<jats:sup>2<\/jats:sup> every 3\u2009weeks. The primary endpoint was the overall response rate, and the secondary endpoints were progression\u2010free survival, overall survival, and the incidence and severity of adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between September 2011 and December 2014, 30 patients were enrolled in this study. The overall response rate was 6.7% (95% confidence interval [CI]: 0.8%\u201322.1%), and the disease control rate was 73.3%. The median progression\u2010free survival was 3.0\u2009months (95% CI: 2.5\u20133.4\u2009months), and the median overall survival was 10.5\u2009months (95% CI: 5.6\u201313.7\u2009months). Grade 3\/4 treatment\u2010related adverse events were reported in \u226510% of the patients, including leukopenia (21%), neutropenia (21%), anemia (17%), anorexia (10%), and hypokalemia (10%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although the treatment\u2010related adverse events were manageable, the combination of weekly irinotecan and S\u20101 did not have the expected effect.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15076","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:28:33Z","timestamp":1692264513000},"page":"2804-2810","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase <scp>II<\/scp> trial of daily S\u20101 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North <scp>Japan<\/scp> lung cancer group 1101"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9824-6572","authenticated-orcid":false,"given":"Yosuke","family":"Kawashima","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine Sendai Kousei Hospital  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ishimoto","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine Sendai Kousei Hospital  Sendai Japan"},{"name":"Okino Medical Clinic  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-6392","authenticated-orcid":false,"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Tohoku University Graduate School of Medicine  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Sakakibara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Tohoku Rosai Hospital  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine JCHO Hokkaido Hospital  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Usui","sequence":"additional","affiliation":[{"name":"Division of Respirology NTT Medical Center Tokyo  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine Tohoku University Graduate School of Medicine  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine Sendai Kousei Hospital  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0232"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2095"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2031"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0981-1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1200"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.0326"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600725"},{"key":"e_1_2_9_10_1","first-page":"492a","article-title":"Randomized multicenter phase III trial of irinotecan (CPT\u201011) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non\u2010small cell lung cancer (NSCLC)","volume":"18","author":"Niho S","year":"1999","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601462"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22208"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.10.022"},{"key":"e_1_2_9_14_1","first-page":"2985","article-title":"Pooled analysis of S\u20101 trials in non\u2010small cell lung cancer according to histological type","volume":"30","author":"Yamamoto N","year":"2010","journal-title":"Anticancer Res"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601335"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyn121"},{"key":"e_1_2_9_17_1","first-page":"246a","article-title":"(topo\u2010I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC)","volume":"18","author":"Ichikawa W","year":"1999","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00541-8"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602139"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-011-0009-5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl066"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0796-9"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1957-0"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu226"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25830"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3690"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100160"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15462"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T23:20:44Z","timestamp":1695597644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":28,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/1759-7714.15076"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15076","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"2023-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}